Once dismissed by some as a shortcut, Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a powerful tool in treating obesity as a chronic disease. With the World Health Organization (WHO) issuing its first global guidelines on their use, we are entering a new era of metabolic medicine